<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2619">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332835</url>
  </required_header>
  <id_info>
    <org_study_id>ABN011-2</org_study_id>
    <nct_id>NCT04332835</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study</brief_title>
  <acronym>CP-COVID-19</acronym>
  <official_title>Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad del Rosario</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Universitaria de Ciencias de la Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CES University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Distrital de Ciencia Biotecnología e Innovacion en Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad del Rosario</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Convalescent plasma (CP) has been used in recent years as an empirical treatment strategy
      when there is no vaccine or treatment available for infectious diseases. In the latest viral
      epidemics, such as the Ebola outbreak in West Africa in 2014, the World Health Organization
      issued a document outlining a protocol for the use of whole blood or plasma collected from
      patients who have recovered from the Ebola virus disease by transfusion to empirically treat
      local infectious outbreaks
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The process is based on obtaining plasma from patients recovered from COVID-19 in Colombia,
      and through a donation of plasma from the recovered, the subsequent transfusion of this to
      patients infected with coronavirus disease (COVID-19). Our group has reviewed the scientific
      evidence regarding the application of convalescent plasma for emergency viral outbreaks and
      has recommended the following protocol
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Single Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Viral Load</measure>
    <time_frame>Days 0, 4, 7, 14 and 28</time_frame>
    <description>Copies of COVID-19 per ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Immunoglobulin G COVID-19 Titers</measure>
    <time_frame>Days 0, 4, 7, 14 and 28</time_frame>
    <description>Immunoglobulin G COVID-19 antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Admission</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>Proportion of patients with Intensive Care Unit Admission requirement (days 7, 14 and 28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit stay</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>Days of Intensive Care Unit management (days 7, 14 and 28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay (days)</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>Days of Hospitalization (days 7, 14 and 28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of mechanical ventilation</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>Proportion of patients with mechanical ventilation (days 7, 14 and 28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (days) of mechanical ventilation</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>Days with mechanical ventilation (days 7, 14 and 28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status assessed according to the World Health Organization guideline</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>1. Hospital discharge; 2. Hospitalization, not requiring supplemental oxygen; 3. Hospitalization, requiring supplemental oxygen (but not Noninvasive Ventilation/ HFNC); 4. Intensive care unit/hospitalization, requiring Noninvasive Ventilation/ HFNC therapy; 5. Intensive care unit, requiring extracorporeal membrane oxygenation and/or invasive mechanical ventilation; 6. Death. (days 7, 14 and 28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>Proportion of death patients at days 7, 14 and 28</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Coronavirus</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol. Simultaneously, they will receive the standard therapy defined by institutional protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants included in the control group will receive standard therapy defined by institutional protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plasma</intervention_name>
    <description>Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.</description>
    <arm_group_label>Intervention Group</arm_group_label>
    <other_name>Convalescent Plasma COVID-19</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Therapy</intervention_name>
    <description>Standard therapy defined by institutional protocol.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Fulfilling all the following criteria

          1. Olerder than 18.

          2. Hospitalized participants with diagnosis of COVID 19 by Real Time - Polymerase Chain
             Reaction.

          3. Severe cases according to the official guideline &quot;Pneumonia Diagnosis and Treatment
             Scheme for Novel Coronavirus Infection (Trial Version 7)&quot;.

          4. Sequential Organ Failure Assessment score (SOFA) &lt; 6.

          5. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Female subjects who are pregnant or breastfeeding.

          2. Patients with prior allergic reactions to transfusions.

          3. Critical ill patients in intensive care units with requierment of Invasive Mechanical
             Venitlation.

          4. Patients with surgical procedures in the last 30 days.

          5. Patients with active treatment for cancer (Radiotherapy or Chemotherapy).

          6. HIV diagnosed patients with viral failure (detectable viral load&gt; 1000 copies / ml
             persistent, two consecutive viral load measurements within a 3 month interval, with
             medication adherence between measurements after at least 6 months of starting a new
             regimen antiretrovirals).

          7. Demonstrated coinfection that explains the patient's symptoms

          8. End-stage chronic kidney disease (Glomerular Filtration Rate &lt;15 ml / min / 1.73 m2).

          9. Child Pugh C stage liver cirrhosis.

         10. High cardiac output diseases.

         11. Autoimmune diseases or Immunoglobulin A nephropathy.

         12. Patients have any condition that in the judgement of the Investigators would make the
             subject inappropriate for entry into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan M Anaya Cabrera, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidad del Rosario</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan M Anaya Cabrera, MD, PhD</last_name>
    <phone>+57 321 233 9828</phone>
    <email>anayajm@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manuel E Rojas Quintana, MD, MSc</last_name>
    <phone>+57 315 459 9951</phone>
    <email>manuel_9316@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidad del Rosario</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>11100</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo Quintero, MD, MSc</last_name>
      <phone>+57 318 3606458</phone>
      <email>gustavo.quintero@urosario.edu.co</email>
    </contact>
    <investigator>
      <last_name>Juan M Anaya Cabrera, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel E Rojas Quintana, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Velez Gomez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan C Diaz Coronado, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anha M Robledo Moreno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan E Gallo Bonilla, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruben D Manrique Hernández, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oscar M Gómez Guzmán, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isaura P Torres Gómez, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paula A Pedroza Rodríguez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernardo Camacho Rodríguez, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeser S Grass Guaqueta, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gustavo A Salguero López, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luisa P Duarte Correales</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristian A Ricaurte Perez, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adriana Rojas Villarraga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heily C Ramírez Santana, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana M Monsalve Carmona, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yhojan A Rodríguez Velandia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yeny Y Acosta Ampudia, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos E Perez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruben D Mantilla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paula Gaviria, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <link>
    <url>https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds</url>
    <description>FDA recommendations for convalescent plasma clinical research</description>
  </link>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020 Jun;92(6):568-576. doi: 10.1002/jmv.25748. Epub 2020 Mar 29. Review.</citation>
    <PMID>32134116</PMID>
  </reference>
  <reference>
    <citation>Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, Ng OT, Marimuthu K, Ang LW, Mak TM, Lau SK, Anderson DE, Chan KS, Tan TY, Ng TY, Cui L, Said Z, Kurupatham L, Chen MI, Chan M, Vasoo S, Wang LF, Tan BH, Lin RTP, Lee VJM, Leo YS, Lye DC; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020 Apr 21;323(15):1488-1494. doi: 10.1001/jama.2020.3204.</citation>
    <PMID>32125362</PMID>
  </reference>
  <reference>
    <citation>Infectious, D. &amp; Outbreaks, D. Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease ( COVID-19 ). OMS 1-5 (2020)</citation>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad del Rosario</investigator_affiliation>
    <investigator_full_name>Juan Manuel Anaya Cabrera</investigator_full_name>
    <investigator_title>MD, PhD, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus Disease 2019</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

